nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

22.11.2021 | original report

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

verfasst von: Xiao Xiao, Xinchen Fang, Wen Yao, Zhu Huaiping

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

Objectives

This study aimed to investigate the clinical characteristics and prognostic impact of 1q21 gain in patients with newly diagnosed multiple myeloma (MM).

Methods

This was a retrospective study of 197 patients with newly diagnosed MM. Fluorescence in situ hybridization was performed to detect six cytogenetic abnormalities: gain(1q21), del(17p), del(13q14), t(4;14), t(14;16), and t(11;14).

Results

We showed that 57.8% of patients with MM had 1q21 gain. The patients with 1q21 gain had lower IgM (0.39 vs 1.14 g/L, P = 0.037) and higher platelet count (177.62109/l vs 148.29109/l, P = 0.018) than those without 1q21 gain, and were more likely to be accompanied by del(13q14) (P < 0.001) or t(4;14) (P = 0.017).

Conclusions

We showed that 1q21 gain was associated with del(13q14) and t(4;14) increase, but it had no effect on prognosis of patients with newly diagnosed MM.

Vorheriger Artikel The outcome of COVID-19 in patients with hematological malignancy

Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–36.CrossRef

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al. Revised international staging system for multiple myeloma: a report from International MYELOMA working group. J Clin Oncol. 2015;33(26):2863–9.CrossRef

Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100–13.CrossRef

Byun JM, Dong-Yeop S, Junshik H, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018;7(3):831–41.CrossRef

Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.CrossRef

Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer. 2005;44(2):194–203.CrossRef

Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defifined unique subset of patients. Blood. 2002;99:3735–41.CrossRef

Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–9.CrossRef

Chiecchio L, Protheroe RKM, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–7.CrossRef

10.

Decaux O, Lodé L, Minvielle S, et al. Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival. Rev Med Interne. 2007;28:677–81.CrossRef

11.

Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.CrossRef

12.

Smol T, Dufour A, Tricot S, et al. Combination of t(4;14),del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Mol Cytogenet. 2017;10:26.CrossRef

13.

Chng WJ, Dispenzieri A, Chim C‑S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77.CrossRef

14.

Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–76. https://doi.org/10.1016/j.mayocp.2013.01.019.CrossRefPubMed

15.

Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548–54.CrossRef

16.

Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95.CrossRef

17.

Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124–32.CrossRef

Titel: Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
verfasst von: Xiao Xiao
Xinchen Fang
Wen Yao
Zhu Huaiping
Publikationsdatum: 22.11.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00774-6

Springer Medizin Österreich

Summary

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

The outcome of COVID-19 in patients with hematological malignancy

BTKi, venetoclax, obinutuzumab: what is the ideal combination?

Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

Checkpoint inhibitor pneumonitis: Short review of literature and case report

Palliative care: patient’s autonomy in the end-of-life situation